Skip to main content
. 2017 Aug 11;26(10):1220–1232. doi: 10.1002/pds.4281

Figure 2.

Figure 2

Kaplan‐Meier persistence curves for persistence to lipid‐lowering medicines in patients with type 2 diabetes by previous CVD. Model 1 adjusted for socioeconomic status; model 2 adjusted for socioeconomic status and concurrent medicines; and model 3 adjusted for socioeconomic status, concurrent medicines, and clinical characteristics